PA
KRYS icon

Parallel Advisors’s Krystal Biotech KRYS Stock Holding History

Parallel Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$631K Buy
1,699
+11
+0.7% +$3.29K 0.01% 696
2026
Q1 		$436K Buy
1,688
+8
+0.5% +$2.13K 0.01% 780
2025
Q4 		$414K Sell
1,680
-183
-10% -$38.5K 0.01% 755
2025
Q3 		$329K Hold
1,863
– – 0.01% 825
2025
Q2 		$256K Buy
1,863
+132
+8% +$19.4K 0.01% 903
2025
Q1 		$312K Sell
1,731
-1,506
-47% -$253K 0.01% 765
2024
Q4 		$507K Hold
3,237
– – 0.01% 576
2024
Q3 		$589K Hold
3,237
– – 0.01% 524
2024
Q2 		$594K Sell
3,237
-15
-0.5% -$2.52K 0.02% 486
2024
Q1 		$579K Sell
3,252
-794
-20% -$110K 0.02% 490
2023
Q4 		$502K Sell
4,046
-125
-3% -$13.9K 0.01% 486
2023
Q3 		$484K Buy
4,171
+53
+1% +$6.47K 0.02% 467
2023
Q2 		$483K Sell
4,118
-11,987
-74% -$1.22M 0.02% 479
2023
Q1 		$1.29M Sell
16,105
-17
-0.1% -$1.34K 0.04% 265
2022
Q4 		$1.28M Sell
16,122
-5,236
-25% -$389K 0.06% 223
2022
Q3 		$1.49M Buy
21,358
+74
+0.3% +$5.35K 0.07% 182
2022
Q2 		$1.4M Sell
21,284
-3,281
-13% -$204K 0.06% 188
2022
Q1 		$1.64M Sell
24,565
-9,471
-28% -$591K 0.07% 196
2021
Q4 		$2.38M Buy
34,036
+28,582
+524% +$1.66M 0.09% 150
2021
Q3 		$285K Hold
5,454
– – 0.01% 589
2021
Q2 		$371K Hold
5,454
– – 0.02% 475
2021
Q1 		$420K Hold
5,454
– – 0.02% 394
2020
Q4 		$327K Hold
5,454
– – 0.02% 430
2020
Q3 		$235K Hold
5,454
– – 0.01% 504
2020
Q2 		$225K Buy
+5,454
New +$262K 0.01% 504

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Parallel Advisors's KRYS Position: Q2 2026 in Review

Parallel Advisors increased its Krystal Biotech (KRYS) stake by 0.65% in Q2 2026, buying an estimated $3.29K and bringing the position to 1,699 shares worth $631K. The position accounts for 0.01% of the portfolio, ranked #696.

Parallel Advisors first reported a position in KRYS in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.38M in Q4 2021. 191 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Parallel Advisors held 1,699 shares of Krystal Biotech worth $631K as of Q2 2026.
  • Parallel Advisors bought 11 Krystal Biotech shares in Q2 2026, an estimated $3.29K.
  • Krystal Biotech made up 0.01% of Parallel Advisors's portfolio in Q2 2026, its #696 holding.
  • Parallel Advisors first reported a position in Krystal Biotech in Q2 2020 and has held it in 25 quarters since.
  • Parallel Advisors's Krystal Biotech position peaked at $2.38M in Q4 2021.
  • 191 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.